Merck And Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Trial After Trodelvy–KEYTRUDA Combination Fails To Achieve Statistically Significant Progression-Free Survival Benefit In First-Line Metastatic NSCLC

뉴스 본문을 불러오고 있어요.

Merck And Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Trial After Trodelvy–KEYTRUDA Combination Fails To Achieve Statistically Significant Progression-Free Survival Benefit In First-Line Metastatic NSCLC | 웨이프 WAPE

Merck And Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Trial After Trodelvy–KEYTRUDA Combination Fails To Achieve Statistically Significant Progression-Free Survival Benefit In First-Line Metastatic NSCLC

기사 요약

관련 종목

댓글 —